Navigation Links
YM BioSciences reports second quarter 2010 operational and financial results
Date:2/8/2010

the products from merging the Australian company, Cytopia Limited, into YM, which occurred January 29, 2010, the Company is currently developing four late-stage products: nimotuzumab, an EGFR-targeting Affinity-Optimized Antibody(TM); a CYT 387 JAK 1/2 small molecule inhibitor, CYT 997, a potent, vascular disrupting agent and AeroLEF(R), a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl. YM has proven regulatory and clinical trial expertise and a diversified business model designed to reduce risk while advancing clinical products toward international approval, marketing and commercialization.

Nimotuzumab is a humanized monoclonal antibody in development worldwide, targeting multiple tumor types primarily in combination with radiation and chemoradiation. It is importantly differentiated from all other currently marketed EGFR-targeting agents due to its remarkably benign side-effect profile. Nimotuzumab's anti-tumor activity has led to its approval for marketing in 23 countries. In more than 9,000 patients reported as having been treated with nimotuzumab worldwide to date, Grade IV incidents of radiation dermatitis and incidents of severe rash have been only rarely observed and reports of the other severe side-effects that are typical of EGFR-targeting molecules have been equally rare. Nimotuzumab is licensed to YM's majority-owned, Canadian subsidiary, CIMYM BioSciences Inc., by CIMAB S.A., and was developed at the Center of Molecular Immunology. Cytopia has two products in clinical development. CYT387 is an oral JAK1/2 inhibitor, originating from the seminal discovery of JAK1 and JAK2 by Dr. Andrew Wilks, the founder of Cytopia. The orally active vascular disrupting agent, CYT997, also arose from this early research. YM is developing AeroLEF for the treatment of moderate to severe acute pain. The product is differentiated from other approaches using opioids
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Neurocrine Biosciences Announces the Appointment of William H. Rastetter to Its Board of Directors
2. Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results
3. Sangamo BioSciences Announces Presentation at BIO CEO & Investor Conference
4. Cellectricon Files Patent Infringement Suit Against Fluxion Biosciences
5. YM BioSciences announces FDA clearance for two ongoing Phase II nimotuzumab trials into USA
6. YM BioSciences announces result of Cytopia shareholder vote
7. Profectus Biosciences to Present at Key Investor Conference in January 2010
8. David L. Macdonald Appointed CEO of GeneLink BioSciences, Inc.
9. YM BioSciences Inc. and Therapure Biopharma Inc. Announce Contract
10. Nu-Tek BioSciences, LLC. Launches Animal-Free, Non-GM Soy Peptone
11. Cardio3 BioSciences Completes Patient Enrolment in First Stage of Pivotal Trial of C-Cure(R) in Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , Jan. 22, 2015   Cypher Genomics, ... Sequenom, Inc. (NASDAQ: SQNM ), the ... agreement for next generation noninvasive prenatal tests (NIPT). ... interpretation technology, called Mantis™, to advance analysis of ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 The report ... by Product Type & Provider Type - Global Advancements, ... market with an in-depth analysis and forecasting of revenues. ... spread through 221 pages and in-depth TOC on “Service ...
(Date:12/24/2014)... 24, 2014   BioLife Solutions , Inc. (NASDAQ: ... clinical grade hypothermic storage and cryopreservation freeze ... cells and tissues  ("BioLife" or the "Company"), today announced that ... May 4, 2015 (the "Annual Meeting"). Because the ...
(Date:12/24/2014)... SoundConnect’s 2015 next ... edge communication technology, provide continued education and inform ... series demonstrates online communication features and benefits; empowering ... most innovative and powerful tools. , According to ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4BioLife Solutions Sets Date for Annual Meeting of Stockholders 2SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3
... compound in sufficient and rapidly produced yields, potentially ... could boost semiconductor capabilities for large-area applications. , ... the first heterometallic gallium-indium hydroxide nanocluster was the ... of nitrosobenzene. , The substitute was identified during ...
... 31 VNUS(R) Medical,Technologies, Inc. (Nasdaq: VNUS ), ... treatment of venous reflux disease, today,announced the hiring of ... Chief Medical Officer., Dr. Smeets joins VNUS with ... Dr. Smeets served as the Head of Clinical Affairs ...
... RANCHO CORDOVA, Calif., Oct. 31 ThermoGenesis,Corp. (Nasdaq: ... and store adult stem cells, announced today it will ... 30, 2008, on,Thursday, November 6, 2008., Company,s Conference ... call Thursday, November 6, 2008 at,2:00 PM Pacific (5:00 ...
Cached Biology Technology:New nanocluster to boost thin films for semiconductors 2VNUS Medical Technologies, Inc. Announces the Hiring of Guido Smeets, MD, as Vice President of Clinical Research and Chief Medical Officer 2ThermoGenesis Corp. to Announce First Quarter Fiscal 2009 Results on November 6, 2008 2
(Date:12/22/2014)... Dec. 22, 2014 Research and Markets ... the "The Global Watermarking and Fingerprinting Markets" ... http://photos.prnewswire.com/prnh/20130307/600769 This insight ... watermarking and fingerprinting markets. Watermarking aims to control ...
(Date:12/19/2014)... 2014  23andMe, Inc., the leading personal genetics company, today announced ... genetic ancestry of individuals from across the United ... than four hundred years ago, the United States ... from different continents. This study illuminates how American history and ...
(Date:12/17/2014)... YORK , Dec. 15, 2014  HITLAB SM ... (GCP) audit to confirm its adherence to current U.S. ... HITLAB to conduct regulated smart device and smart phone ... and research quality. "HITLAB is determined to ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2
... In neurodegenerative diseases, clumps of insoluble proteins appear in ... to each disease, such as amyloid beta in Alzheimer,s ... many other insoluble proteins that are normally present in ... these other proteins were thought to be accidental inclusions ...
... has detected and quantified novel small RNAs in human ... molecules, confirming a long-held but unproven hypothesis that mammalian ... molecules directly. The findings were reported in Nature ... School of Medicine , Helicos Biosciences Corp., Integromics Inc., ...
... received the prestigious Coulter Foundation Translational Awards for promising ... The Coulter program provides funding for ... Initial funding for each professor will be at ... NJIT Associate Professor Treena Arinzeh will receive funding for ...
Cached Biology News:Proteins linked with Alzheimer's, other neurodegenerative diseases found to clump in normal aging 2Proteins linked with Alzheimer's, other neurodegenerative diseases found to clump in normal aging 3Human cells can copy not only DNA, but also RNA, says team from Pitt, Helicos BioSciences 2Stem cell, artificial liver research receives Coulter Foundation funding at NJIT 2
... Dithiothreitol DTT ... INERT GAS. Purity: ≥99% ... metals: Absorbance: (100 ... Soluble in EtOH or H ...
... White solid.. PACKAGED UNDER INERT GAS. ... reaction is "driven" to completion. A protective agent ... found in many other preparations. Blocks the lethal ... by titration. Contaminants: Heavy metals: ≤1 ...
... Faster speeds, highest precision, more user-friendliness ... concept: this is the definition of the ... years nucleic acid research has been developing ... required of PCR Systems. To keep ...
... The recent sequencing of Salmonella genomes ... enterica Typhimurium ORFmer PCR* primer pairs. The ... of a single chromosome (4,857,432 bp; 4,440 ... 107 ORFs). These ORFmers from Sigma-Genosys have ...
Biology Products: